Home › Calculator › HALO Dividend Calculator 2026
HALO Dividend DRIP Calculator 2026
2.52% YieldHealthcareHalozyme Therapeutics, Inc. · NASDAQ
Price: $79.46 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When HALO pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your HALO snowball 📈
$10,000 in HALO → $10.50M in 10 years · $21.51/month
About Halozyme Therapeutics, Inc. (HALO) — Dividend Analysis 2026
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Compare HALO with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full HALO DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open HALO position with:
🌍 HALO Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold HALO.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.52% | -0.28% | $252 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.14% | -0.66% | $214 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.02% | -0.78% | $202 / yr |
| 🇬🇧 UK ISA | 0% | 2.52% | -0.28% | $252 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.30% | -0.50% | $230 / yr |
| 🇨🇦 TFSA | 0% | 2.52% | -0.28% | $252 / yr |
| 🇨🇦 CA Taxable | 25% | 1.89% | -0.91% | $189 / yr |
| 🇦🇺 Super (pension) | 15% | 2.14% | -0.66% | $214 / yr |
| 🇦🇺 AU Taxable | 30% | 1.76% | -1.04% | $176 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.86% | -0.94% | $186 / yr |
| 🇫🇷 FR Taxable | 30% | 1.76% | -1.04% | $176 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 HALO Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 HALO Dividend Payment Schedule
HALO pays quarterly — 4 times per year. Next ex-div: TBD.
📊 HALO vs Healthcare Benchmarks
How HALO compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for HALO sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ HALO Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2026-07-08 | 1,923 | $12.07 | $23.2K | ||
| Sale | 2026-07-08 | 888 | $79.28 | $70.4K | ||
| Sale | 2026-07-08 | 1,035 | $80.19 | $83.0K | ||
| M-Exempt | 2026-07-08 | 1,923 | $12.07 | $23.2K | ||
| A-Award | 2026-07-01 | 39,823 | $77.01 | $3.07M | ||
| A-Award | 2026-07-01 | 16,232 | — | — | ||
| M-Exempt | 2026-06-30 | 10,000 | — | — | ||
| F-InKind | 2026-06-30 | 5,408 | $78.27 | $423.3K | ||
| M-Exempt | 2026-06-30 | 10,000 | — | — | ||
| A-Award | 2026-07-01 | 127,432 | $77.01 | $9.81M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where HALO earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the HALO dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Halozyme Therapeutics, Inc. (HALO) is currently trading at $79.46, trading near its 52-week high. The current dividend yield is 2.52% based on an annual payout of $2.00 per share.
HALO (Halozyme Therapeutics, Inc.) — 2.52% Dividend Yield Analysis
Halozyme Therapeutics, Inc. (HALO) is a healthcare stock currently trading at $79.46 with a dividend yield of 2.52%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.